Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Pilot Study of the Oral mTOR Inhibitor RAD001 in Combination With Capecitabine for Metastatic Breast Cancer

NCT00473005 is registered in ClinicalTrials.gov with Stanford University as lead sponsor.

NCT NCT00473005
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00473005 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Pilot Study of the Oral mTOR Inhibitor RAD001 in Combination With Capecitabine for Metastatic Breast Cancer
Lead sponsor
Stanford University
Phase
Phase 1
Overall status
Terminated
Start date
August 31, 2007
Completion date
December 31, 2011
Enrollment
18 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer